The role of insulin resistance in diabetic neuropathy in Koreans with type 2 diabetes mellitus: A 6-year follow-up study

Yonsei Medical Journal

Volumn 55, Issue 3, 2014, Pages 700-708

  Cho, Yu Na ^a   Lee, Kee Ook ^b   Jeong, Julie ^c   Park, Hyung Jun ^d   Kim, Seung Min ^a   Shin, Ha Young ^a   Hong, Ji Man ^e   Ahn, Chul Woo ^a   Choi, Young Chul ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Konyang University College of Medicine   (South Korea)

^c Wonkwang University   (South Korea)

^d Ewha Womans University School of Medicine   (South Korea)

^e Yonsei University   (South Korea)

Author keywords

Diabetic neuropathy; Insulin resistance; Metabolic syndrome; Type 2 diabetes mellitus

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN LISPRO; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ACTION POTENTIAL; ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; ELECTROMYOGRAPHY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; KOREA; MALE; MICHIGAN DIABETIC NEUROPATHY SCORE; MIDDLE AGED; MUSCLE STRENGTH; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; PLASMA HALF LIFE; RADIOIMMUNOASSAY; SCORING SYSTEM; SENSORY NERVE ACTION POTENTIAL; SENSORY NERVE CONDUCTION; VIBRATION SENSE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; STATISTICAL MODEL;

ADULT; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; HUMANS; INSULIN RESISTANCE; LOGISTIC MODELS; MALE; MIDDLE AGED;

EID: 84898759053     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2014.55.3.700     Document Type: Article

References (31)

1. Bruce KD, Hanson MA. The developmental origins, mechanisms, and implications of metabolic syndrome. J Nutr 2010; 140: 648-52.
2. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med 2006; 119(5 Suppl 1): S10-6.
3. Kim DJ, Song KE, Park JW, Cho HK, Lee KW, Huh KB. Clinical characteristics of Korean type 2 diabetic patients in 2005. Diabetes Res Clin Pract 2007; 77 Suppl 1: S252-7.
4. Lee KO, Nam JS, Ahn CW, Hong JM, Kim SM, Sunwoo IN, et al. Insulin resistance is independently associated with peripheral and autonomic neuropathy in Korean type 2 diabetic patients. Acta Diabetol 2012; 49: 97-103.
5. Bril V. NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Eur Neurol 1999; 41 Suppl 1: 8-13.
6. Dyck PJ, Lais A, Karnes JL, O'Brien P, Rizza R. Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy. Ann Neurol 1986; 19: 425-39.
7. Said G. Diabetic neuropathy--a review. Nat Clin Pract Neurol 2007; 3: 331-40.
8. Karsidag S, Morali S, Sargin M, Salman S, Karsidag K, Us O. The electrophysiological findings of subclinical neuropathy in patients with recently diagnosed type 1 diabetes mellitus. Diabetes Res Clin Pract 2005; 67: 211-9.
9. Abu-Shakra SR, Cornblath DR, Avila OL, Chaudhry V, Freimer M, Glass JD, et al. Conduction block in diabetic neuropathy. Muscle Nerve 1991; 14: 858-62.
10. Viader A, Sasaki Y, Kim S, Strickland A, Workman CS, Yang K, et al. Aberrant Schwann cell lipid metabolism linked to mitochondrial deficits leads to axon degeneration and neuropathy. Neuron 2013; 77: 886-98.
11. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994; 17: 1281-9.
12. Im S, Kim SR, Park JH, Kim YS, Park GY. Assessment of the medial dorsal cutaneous, dorsal sural, and medial plantar nerves in impaired glucose tolerance and diabetic patients with normal sural and superficial peroneal nerve responses. Diabetes Care 2012; 35: 834-9.
13. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26 Suppl 1: S5-20.
14. England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT, et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005; 64: 199-207.
15. Gelding SV, Robinson S, Lowe S, Niththyananthan R, Johnston DG. Validation of the low dose short insulin tolerance test for evaluation of insulin sensitivity. Clin Endocrinol (Oxf) 1994; 40: 611-5.
16. Dyck PJ, Davies JL, Clark VM, Litchy WJ, Dyck PJ, Klein CJ, et al. Modeling chronic glycemic exposure variables as correlates and predictors of microvascular complications of diabetes. Diabetes Care 2006; 29: 2282-8.
17. Albers JW, Herman WH, Pop-Busui R, Martin CL, Cleary P, Waberski B, et al. Subclinical neuropathy among Diabetes Control and Complications Trial participants without diagnosable neuropathy at trial completion: possible predictors of incident neuropathy? Diabetes Care 2007; 30: 2613-8.
18. Turner N, Heilbronn LK. Is mitochondrial dysfunction a cause of insulin resistance? Trends Endocrinol Metab 2008; 19: 324-30.
19. Kim B, McLean LL, Philip SS, Feldman EL. Hyperinsulinemia induces insulin resistance in dorsal root ganglion neurons. Endocrinology 2011; 152: 3638-47.
20. Höke A. Animal models of peripheral neuropathies. Neurotherapeutics 2012; 9: 262-9.
21. Vincent AM, Hayes JM, McLean LL, Vivekanandan-Giri A, Pennathur S, Feldman EL. Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes 2009;58:2376-85.
22. Vincent AM, Hinder LM, Pop-Busui R, Feldman EL. Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Peripher Nerv Syst 2009; 14: 257-67.
23. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008; 102(10 Suppl): 1K-34K.
24. Woo V, Shestakova MV, Ørskov C, Ceriello A. Targets and tactics: the relative importance of HbA, fasting and postprandial plasma glucose levels to glycaemic control in type 2 diabetes. Int J Clin Pract 2008; 62: 1935-42.
25. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
26. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-96.
27. American Diabetes Association. Standards of medical care in diabetes--2012. Diabetes Care 2012; 35 Suppl 1: S11-63.
28. El-Salem K, Ammari F, Khader Y, Dhaimat O. Elevated glycosylated hemoglobin is associated with subclinical neuropathy in neurologically asymptomatic diabetic patients: a prospective study. J Clin Neurophysiol 2009; 26: 50-3.
29. Smith AG. Impaired glucose tolerance and metabolic syndrome in idiopathic neuropathy. J Peripher Nerv Syst 2012; 17 Suppl 2: 15-21.
30. Aaberg ML, Burch DM, Hud ZR, Zacharias MP. Gender differences in the onset of diabetic neuropathy. J Diabetes Complications 2008; 22: 83-7.
31. Booya F, Bandarian F, Larijani B, Pajouhi M, Nooraei M, Lotfi J. Potential risk factors for diabetic neuropathy: a case control study. BMC Neurol 2005; 5: 24.